中国临床药理学与治疗学2011，Vol.16Issue(12)：1397-1402,6.
CYP2C19基因多态性对中国人体内兰索拉唑药代动力学及其5-羟基代谢通路的影响
Effect of CYP2C19 genetic polymorphism on pharmacokinetic characterstics and 5-hydroxyl metabolic pathway of lansoprazole in Chinese volunteers
摘要
Abstract
AIM: To investigate the effect of CYP2C19 polymorphism on pharmacokinetic characteristics and 5-hydroxyl metabolic pathway of lansoprazole in Chinese subjects. METH-ODS: Twelve healthy subjects were typed by u-sing RFLP-PCR method. After intravenous drip 30 mg lansoprazole, the plasma concentrations of lansoprazole in subjects were determined byLC-MS method. The pharmacokinetic parameters of lansoprazole and AUClpz/AUC5-Ohlpz were calculated and compared between different groups. RESULTS-. After all the subjects were given 30 mg lansoprazole, it found that the AUCo-,, AUCo-(x), CLz, ( AUCLpz/ AUC5-oh)0-t, and (AUCLpZ/AUC5-oh)0-∞ of the mutant types were equivalent to 2.381, 2.572, 0. 428, 3. 602 and 4. 083-fold as those of the wild types, respectively. CONCLUSION: The CYP2C19 genetic polymorphism, which has significant influence on the pharmacokinetic characteristics of the lansoprazole in Chinese volun-teers (P<0. 05), has very significant influence on the 5-hydroxyl metabolic pathway of the lansoprazole (P<0. 01). The result suggests that CYP2C19 genetic polymorphism is one of the important factors leading to individual concentration differences of the lansoprazole and has a better relevance with the 5-hydroxyl metabolic pathway.关键词
CYP2C19/基因多态性/兰索拉唑/药代动力学Key words
CYP2C19/Polymorphism,Lansoprazole/Pharmacokinetics分类
医药卫生引用本文复制引用
严非,夏春华,熊玉卿..CYP2C19基因多态性对中国人体内兰索拉唑药代动力学及其5-羟基代谢通路的影响[J].中国临床药理学与治疗学,2011,16(12):1397-1402,6.基金项目
国家十一五科技重大专项(2009ZX09309-003-02) （2009ZX09309-003-02）
国家十二五科技重大专项(2011ZX09302-007-03) （2011ZX09302-007-03）
